Susan Holliday
About Susan Holliday
Global insurance executive and seasoned board director appointed as a Class III director at Hippo effective October 1, 2025, with an initial term expiring at the 2027 annual meeting. She serves on the Audit, Risk, and Compliance Committee and the Compensation Committee, with no related‑party transactions or family relationships disclosed in connection with her appointment. Age and formal education are not disclosed in Hippo filings; prior background includes senior roles at Swiss Re and experience across UBS and the World Bank. Independence determination is not explicitly stated in the 8‑K, but no material interests under Item 404(a) were reported.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Swiss Re (Global Executive Team) | Led strategy for $24.5B reinsurance business; advised early insurtech investments | Not disclosed | Advanced initiatives such as IFC Women and Insurance program |
| UBS | Executive/leadership capacity (capital markets expertise) | Not disclosed | Global risk oversight experience |
| World Bank/IFC initiatives | Advisor/leader on diversity programs | Not disclosed | Advanced IFC Women and Insurance program |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Acrisure Re | Director | Not disclosed | Chaired Audit and Risk Committees across regulated markets (Europe, Africa) |
| Tangerine Financial | Director | Not disclosed | Chaired Audit and Risk Committees across regulated markets (Europe, Africa) |
Board Governance
- Class assignment and term: Class III director effective October 1, 2025; term to expire at the 2027 annual meeting.
- Committee assignments: Audit, Risk, and Compliance Committee (member); Compensation Committee (member).
- Attendance: Not yet disclosed for Ms. Holliday; Hippo reported each director attended at least 75% of Board and committee meetings in FY2024 (pre‑appointment context).
- Independence and conflicts: No arrangements/understandings for election, no family relationships, and no transactions requiring disclosure under Item 404(a).
- Governance policies: Non‑employee director stock ownership guidelines require 5x annual retainer within five years; anti‑hedging policy prohibits directors from entering hedging transactions.
Fixed Compensation
| Component | Amount (USD) | Effective/Notes |
|---|---|---|
| Annual Board retainer | $60,000 | For non‑employee directors |
| Audit Committee member fee | $10,000 | Annual cash compensation |
| Compensation Committee member fee | $6,000 | Annual cash compensation |
| Appointment effective date | October 1, 2025 | Class III |
Performance Compensation
| Award Type | Value/Structure | Vesting | Change‑of‑Control |
|---|---|---|---|
| Initial RSU grant | Valued at $130,000 (30‑day average price; prorated Oct 1, 2025–Jun 3, 2026) | Vests in full on June 3, 2026, subject to continued service | All equity awards accelerate in full upon change in control as defined in 2021 Plan |
| Annual RSU (post next annual meeting) | Valued at $130,000 (30‑day average price) | Vests on the earlier of 1‑year anniversary or immediately prior to next annual meeting, subject to continued service | All equity awards accelerate in full upon change in control |
| Performance metrics | None disclosed for director awards; awards are time‑based | — | — |
Other Directorships & Interlocks
- Current boards: Acrisure Re; Tangerine Financial (audit/risk chair roles across regulated markets).
- Interlocks/related party exposure with Hippo: None disclosed under Item 404(a) in connection with appointment.
Expertise & Qualifications
- Insurance and reinsurance strategy leadership (Swiss Re global executive team; $24.5B reinsurance business).
- Capital markets and global risk oversight (experience spanning UBS and World Bank/IFC initiatives).
- Board governance maturity and audit/risk chair experience across Europe and Africa.
Equity Ownership
| Item | Detail |
|---|---|
| Initial beneficial ownership (Form 3) | No securities beneficially owned as of October 1, 2025; Form 3 filed October 3, 2025 |
| Scheduled equity awards | Eligible for initial prorated RSU valued at $130,000 (vest 6/3/2026); eligible for annual RSU valued at $130,000 post next annual meeting |
| Hedging/Pledging | Hedging prohibited by Insider Trading Policy; no pledging disclosures noted |
| Ownership guidelines | Must reach 5x annual retainer within five years of election (i.e., by October 1, 2030), per Board policy |
Governance Assessment
- Strengths: Appointment to Audit and Compensation committees signals confidence in her risk oversight, financial acumen, and pay governance; time‑based RSUs with clear vesting and change‑of‑control mechanics are standard and transparent; anti‑hedging policy and 5x retainer ownership guidelines support alignment over time.
- Independence/Conflict posture: No family relationships or related‑party transactions disclosed upon appointment; Item 404(a) clean, reducing conflict risk.
- Engagement/Alignment watchpoints: As a new director with initial Form 3 showing no holdings, ownership alignment will build through RSU accrual and guideline compliance over the five‑year window; attendance and committee engagement will be assessed in the next proxy cycle.
RED FLAGS: None disclosed specific to Ms. Holliday at appointment (no Item 404(a) transactions; no family relationships). Monitoring points include future equity holdings, attendance in FY2025‑2026, and any emerging related‑party exposures via external boards.